Table 3 Demographics and baseline characteristics between patients with severe and non-severe respiratory complications

Age in years (mean ± SE)

36.3 (± 3.8)

28.9 (± 4.5)

45.9 (± 5.8)

Sex (m/f)

12/18

6/11

6/7

Comorbidities and concomitant conditions (n/%)

17 (56.7)

6 (35.3)

11 (84.6)

Respiratory symptoms at hospital admission (n/%)

23 (76.7)

12 (70.6)

11 (84.6)

Time of previous symptoms (days—mean ± SE)

6 (± 0.6)

6.7 (± 0.8)

5.1 (± 0.9)

Fever on admission (n/%)

12 (40)

9 (52.9)

3 (23.1)

First malaria episode (n/%)^a

7 (23.3)

3 (17.6)

4 (30.7)

Respiratory complications after anti-malarials (n/%)

18 (60)

9 (52.9)

9 (69.2)

Anti-malarial treatment before hospitalization (n/%)

15 (50)

5 (29.4)

10 (76.9)

Patients requiring haemodialysis (n/%)

5 (16.7)

1 (5.9)

4 (30.7)

Death (n/%)

5 (16.6)

1 (5.9)

4 (30.7)

Haemoglobin (g/dL) (mean ± SE)

9.6 (± 0.4)

9.9 (± 0.5)

9.1 (± 0.6)

Leucocytes (× 10³/mm³) median (IQR)

6.5 (4.4–10.8)

5.3 (3.7–9.5)

8 (6.5–12.8)

Platelet count (× 10³/mm³) median (IQR)

49.5 (31–91)

36 (28–51)

79 (66–101)

Creatinine (mg/dL) median (IQR)^b

1 (0.8–1.5)

0.9 (0.7–1.2)

1 (0.9–2.3)

Urea (mg/dL) median (IQR)^b

31 (24–69)

31 (23–42)

41 (24–88)

Bilirubin (mg/dL) median (IQR)^c

1.6 (0.7–4.7)

2.2 (0.5–3.6)

0.9 (0.7–10)

Lactate dehydrogenase (U/L) (mean ± SE)^d

911.7 (± 91.2)

809.2 (± 86.4)

1034.6 (± 169)

AST (U/L) median (IQR)

50 (31–59)

50 (29–57)

50 (35–94)

ALT(U/L) median (IQR)

31 (25–60)

31 (35–66)

32 (25–54)

GGT (U/L) median (IQR)

107 (53–192)

75 (52–128)

141 (71–217)

Alkaline Phosphatase (U/L) (mean ± SE)^e

384 (± 53)

329 (± 50)

501 (± 125)